Livagen Dosage: Longevity Research Protocol

Read this first

Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.

Dosage chart

The dosage amounts and schedules below come only from PeptideDosages.com. Syringe-unit figures are mathematical conversions of those source amounts using exactly 3 ml of bacteriostatic water. Educational reference only — not instructions or medical advice.

Livagen · 20 mg Vial

Livagen is dosed at 500 mcg–2 mg daily via subcutaneous injection in educational protocols.

Typical daily range: 0.5–2.0 mg once daily (gradual titration over 8–12 weeks).

Standard / Gradual Approach

Week	Daily Dose (mg)
Weeks 1–2	0.5 mg (500 mcg)
Weeks 3–4	1.0 mg (1000 mcg)
Weeks 5–6	1.5 mg (1500 mcg)
Weeks 7–12	2.0 mg (2000 mcg)

3 ml conversion

Select vial strength

20 mg + 3 ml = 6.67 mg/ml. Choose your vial strength to update the units below.

Source dose	U-100 syringe
0.5 mg	7.5 units
1 mg	15 units
1.5 mg	23 units
2 mg	30 units

Source chart on peptidedosages.com

Other longevity compounds

MOTS-cMitochondrial-derived peptide (16 amino acids)NAD+Nicotinamide adenine dinucleotide coenzyme VesugenSynthetic tripeptide bioregulator (vascular sequence)CartalaxSynthetic tripeptide (Ala-Glu-Asp) bioregulator EpithalonSynthetic tetrapeptide (Ala-Glu-Asp-Gly)FOXO4-DRIFOXO4-p53 interaction-disrupting retro-inverso peptide

All research protocols

Livagen: research background

What the compound is

Livagen is a synthetic short peptide with the sequence Lys-Glu-Asp-Ala (PMID 15085253, PMID 12942748). It is classified as a peptide bioregulator (PMID 25541832, PMID 37042594).

How it is thought to work

Livagen appears to modify chromatin, influencing processes like deheterochromatinization (decondensation) of various chromatin regions (PMID 25541832, PMID 15085253, PMID 17460203, PMID 12533768, PMID 16705247). This deheterochromatinization can lead to the activation of ribosomal genes and the release of genes repressed due to age-related chromatin condensation in cells (PMID 15085253, PMID 12533768, PMID 16705247). It has been observed to have a selective effect on definite regions of chromosomes (PMID 37042594). In vitro studies also suggest Livagen can inhibit enkephalin-degrading enzymes from human serum (PMID 12942748).

What laboratory and animal studies report

In organotypic cultures, Livagen stimulated the growth of explants from rat brain cortex (animal study, PMID 11713572). In human serum assays, Livagen demonstrated inhibitory effects on enkephalin-degrading enzymes, with an IC50 of 20 microM. It was more efficient than certain known peptidase inhibitors (in vitro study, PMID 12942748). No interaction was observed between Livagen and mu- or delta-opioid receptors in membrane fractions from rat brains (animal study, PMID 12942748).

Human evidence so far

In cultured lymphocytes from individuals aged 75-88 years or 80 years and older, Livagen was shown to activate ribosomal genes, induce decondensation of densely packed chromatin fibrils, and deheterochromatinize facultative chromatin (cell study, PMID 15085253, PMID 12533768, PMID 16705247). Livagen also promoted the normalization of altered genomic indicators related to atherosclerosis in lymphocytes from patients aged 80 years and older, and 30-35 years old, suggesting a modifying influence on chromatin (cell study, PMID 25541832). It was effective in decreasing the number of chromosomal changes induced by CoCl2 in cultured lymphocytes from old individuals (cell study, PMID 17460203).

Key terms explained

Chromatin refers to the complex of DNA and proteins that forms chromosomes within the nucleus of eukaryotic cells. It can be tightly packed (condensed) or more relaxed (decondensed) (PMID 25541832, PMID 15085253). Heterochromatin is a densely packed form of chromatin, often associated with inactive genes, while euchromatin is a more open form, typically associated with active genes (PMID 15085253, PMID 17460203). Deheterochromatinization is the process where densely packed chromatin becomes less condensed, which can lead to the reactivation of genes (PMID 15085253, PMID 17460203, PMID 12533768).

Studies cited in this section

[Genomic instability in atherosclerosis]. — Georgian medical news, 2014 (PMID 25541832)
Effects of short peptides on lymphocyte chromatin in senile subjects. — Bulletin of experimental biology and medicine, 2004 (PMID 15085253)
Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. — Annals of the New York Academy of Sciences, 2007 (PMID 17460203)
Tissue-specific effects of peptides. — Bulletin of experimental biology and medicine, 2001 (PMID 11713572)
EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN. — Georgian medical news, 2023 (PMID 37042594)
Anti-aging peptide bioregulators induce reactivation of chromatin. — Georgian medical news, 2006 (PMID 16705247)
Effects of Livagen peptide on chromatin activation in lymphocytes from old people. — Bulletin of experimental biology and medicine, 2002 (PMID 12533768)
[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]. — Izvestiia Akademii nauk. Seriia biologicheskaia, 2003 (PMID 12942748)

Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.

Nearby in the protocol A–Z

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.

Livagen dosage protocol